» Articles » PMID: 19533749

Artemisinin Dimer Anticancer Activity Correlates with Heme-catalyzed Reactive Oxygen Species Generation and Endoplasmic Reticulum Stress Induction

Overview
Journal Int J Cancer
Specialty Oncology
Date 2009 Jun 18
PMID 19533749
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Analogs of the malaria therapeutic, artemisinin, possess in vitro and in vivo anticancer activity. In this study, two dimeric artemisinins (NSC724910 and 735847) were studied to determine their mechanism of action. Dimers were >1,000 fold more active than monomer and treatment was associated with increased reactive oxygen species (ROS) and apoptosis induction. Dimer activity was inhibited by the antioxidant L-NAC, the iron chelator desferroxamine and exogenous hemin. Similarly, induction of heme oxygenase (HMOX) with CoPPIX inhibited activity, whereas inhibition of HMOX with SnPPIX enhanced it. These results emphasize the importance of iron, heme and ROS in activity. Microarray analysis of dimer treated cells identified DNA damage, iron/heme and cysteine/methionine metabolism, antioxidant response, and endoplasmic reticulum (ER) stress as affected pathways. Detection of an ER-stress response was relevant because in malaria, artemisinin inhibits pfATP6, the plasmodium orthologue of mammalian sarcoplasmic/endoplasmic reticulum Ca(2+)-ATPases (SERCA). A comparative study of NSC735847 with thapsigargin, a specific SERCA inhibitor and ER-stress inducer showed similar behavior in terms of transcriptomic changes, induction of endogenous SERCA and ER calcium mobilization. However, thapsigargin had little effect on ROS production, modulated different ER-stress proteins and had greater potency against purified SERCA1. Furthermore, an inactive derivative of NSC735847 that lacked the endoperoxide had identical inhibitory activity against purified SERCA1, suggesting that direct inhibition of SERCA has little inference on overall cytotoxicity. In summary, these data implicate indirect ER-stress induction as a central mechanism of artemisinin dimer activity.

Citing Articles

Design and Mechanism Study of 6c, a Novel Artesunate Derivatives, for Anti-Hepatocellular Carcinoma.

Xiong S J Hepatocell Carcinoma. 2025; 12:149-167.

PMID: 39881675 PMC: 11776411. DOI: 10.2147/JHC.S490445.


Neuroprotective effects and mechanisms of action of artemisinin in retinal ganglion cells in a mouse model of traumatic optic neuropathy.

Zhou S, Li W, Lv R, Zhang M, Liu W Heliyon. 2024; 10(11):e31378.

PMID: 38828288 PMC: 11140598. DOI: 10.1016/j.heliyon.2024.e31378.


In Vivo and Clinical Studies of Natural Products Targeting the Hallmarks of Cancer.

Elbadawi M, Efferth T Handb Exp Pharmacol. 2024; 287():95-121.

PMID: 38797749 DOI: 10.1007/164_2024_716.


Targeting ferroptosis for leukemia therapy: exploring novel strategies from its mechanisms and role in leukemia based on nanotechnology.

Ashoub M, Razavi R, Heydaryan K, Salavati-Niasari M, Amiri M Eur J Med Res. 2024; 29(1):224.

PMID: 38594732 PMC: 11003188. DOI: 10.1186/s40001-024-01822-7.


Induction and application of ferroptosis in cancer therapy.

Nie Q, Hu Y, Yu X, Li X, Fang X Cancer Cell Int. 2022; 22(1):12.

PMID: 34996454 PMC: 8742449. DOI: 10.1186/s12935-021-02366-0.


References
1.
Thastrup O, Cullen P, Drobak B, Hanley M, Dawson A . Thapsigargin, a tumor promoter, discharges intracellular Ca2+ stores by specific inhibition of the endoplasmic reticulum Ca2(+)-ATPase. Proc Natl Acad Sci U S A. 1990; 87(7):2466-70. PMC: 53710. DOI: 10.1073/pnas.87.7.2466. View

2.
Li Y, Wu Y . How Chinese scientists discovered qinghaosu (artemisinin) and developed its derivatives? What are the future perspectives?. Med Trop (Mars). 1999; 58(3 Suppl):9-12. View

3.
Efferth T, Dunstan H, Sauerbrey A, Miyachi H, Chitambar C . The anti-malarial artesunate is also active against cancer. Int J Oncol. 2001; 18(4):767-73. DOI: 10.3892/ijo.18.4.767. View

4.
Kijima Y, Ogunbunmi E, Fleischer S . Drug action of thapsigargin on the Ca2+ pump protein of sarcoplasmic reticulum. J Biol Chem. 1991; 266(34):22912-8. View

5.
Efferth T . Molecular pharmacology and pharmacogenomics of artemisinin and its derivatives in cancer cells. Curr Drug Targets. 2006; 7(4):407-21. DOI: 10.2174/138945006776359412. View